Skip to nav Skip to content

ASCO/IDSA Webinar: The COVID-19 Vaccine & Patients with Cancer

Facebook Twitter LinkedIn Email

On December 17 at 3:00 PM Eastern, the American Society of Clinical Oncology and the Infectious Diseases Society of America hosted a panel discussion on the use of the COVID-19 vaccines for cancer patients. The panel included experts in infectious diseases and oncology, and discussed available data on vaccine safety and efficacy, use of vaccines in immunocompromised patients, and management of adverse reactions.


  • Dana S. Wollins, DrPH, MGC
    Vice President, Clinical Affairs & Practice Guidelines, IDSA


  • Stephen S. Grubbs, MD, FASCO
    Vice President, Clinical Affairs
    American Society of Clinical Oncology (ASCO)

Featured Panelists

  • Joshua A. Hill
    MD Assistant Professor, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center
    Assistant Professor, Division of Allergy and Infectious Diseases, University of Washington

  • Michael G. Ison, MD, MS, FIDSA, FAST
    Professor, Divisions of Infectious Diseases and Organ Transplantation
    Northwestern University Feinberg School of Medicine
    Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
    Director, Center for Clinical Research
    Northwestern University Clinical and Translational Sciences Institute

  • Gary H. Lyman, MD, MPH (Biostatistics), FASCO, FACP, FRCP
    Professor, Public Health Sciences and Clinical Research Divisions, Fred Hutchinson Cancer Research Center
    Senior Lead, Healthcare Quality and Policy, Hutchinson Institute for Cancer Outcomes Research
    Professor of Medicine, Public Health and Pharmacy, University of Washington School of Medicine
    Executive Officer, SWOG Cancer Research Network

This website uses cookies

We use cookies to ensure that we give you the best experience on our website. Cookies facilitate the functioning of this site including a member login and personalized experience. Cookies are also used to generate analytics to improve this site as well as enable social media functionality.